A clinical trial of beclomethasone dipropionate aerosol in seasonal respiratory allergy is reported. Complete control was never achieved, due to acute antigen challenges at the peaks of pollen or spore counts. In ninety-live asthma cases 66.3%, had good control, 10.5% moderate control and 23.2% were failures. In seventy-two hay fever cases, using nasal applicators for the aerosol, 71% had good and 7% moderate control, while 22% were failures of treatment.
Steroid aerosol therapy for seasonal respiratory allergy appears to be a satisfactory treatment, free from side effects, and particularly suitable for patients where there are contra-indications to oral steroid therapy, such as peptic ulcer or diabetes mellitus.